E-Cadherin Protein Expression Predicts Prostate Cancer Salvage Radiotherapy Outcomes

Michael E. Ray, Rohit Mehra, Howard M. Sandler, Stephanie Daignault, Rajal B. Shah

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Purpose: Radiotherapy for biochemical prostate cancer recurrence after prostatectomy achieves durable salvage rates of only 40% to 50%. Improved methods of identifying patients unlikely to benefit from salvage radiotherapy are needed. Altered expression of the adhesion molecule E-cadherin may be associated with the invasive and metastatic phenotype. We examined the relationship between E-cadherin expression and outcomes after salvage radiotherapy. Materials and Methods: E-cadherin expression was examined by immunohistochemistical analysis of a tissue microarray of prostatectomy tissues from patients who underwent salvage radiotherapy. The relation between E-cadherin staining, other risk factors and biochemical failure after salvage radiotherapy was analyzed using Kaplan-Meier and Cox regression methods. Results: Of 37 analyzable cases 25 showed aberrant E-cadherin expression, while the remainder had normal expression. At a median clinical followup of 40 months univariate analysis demonstrated that E-cadherin staining was not associated with Gleason score, extracapsular extension, surgical margin status, pre-prostatectomy or pre-radiotherapy prostate specific antigen, complete biochemical response after radiotherapy or adjunctive hormonal therapy but it was associated with seminal vesicle invasion. Two-year failure-free survival was 55% in patients with aberrant E-cadherin expression compared with 92% in patients with normal E-cadherin expression (p = 0.02). Multivariate analysis confirmed that aberrant E-cadherin expression was associated with salvage radiotherapy failure (p = 0.03). Conclusions: Aberrant E-cadherin staining is associated with increased biochemical failure rates after salvage radiotherapy. Patients with biochemical failure after prostatectomy and aberrant E-cadherin expression are likely to have subclinical disseminated disease. Early systemic therapy may be warranted in these patients.

Original languageEnglish (US)
Pages (from-to)1409-1414
Number of pages6
JournalJournal of Urology
Volume176
Issue number4
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Cadherins
Prostatic Neoplasms
Radiotherapy
Proteins
Prostatectomy
Staining and Labeling
Tissue Array Analysis
Neoplasm Grading
Seminal Vesicles
Prostate-Specific Antigen
Secondary Prevention
Multivariate Analysis
Phenotype
Recurrence
Survival

Keywords

  • cadherins
  • prostate
  • prostatic neoplasms
  • radiotherapy
  • salvage therapy

ASJC Scopus subject areas

  • Urology

Cite this

E-Cadherin Protein Expression Predicts Prostate Cancer Salvage Radiotherapy Outcomes. / Ray, Michael E.; Mehra, Rohit; Sandler, Howard M.; Daignault, Stephanie; Shah, Rajal B.

In: Journal of Urology, Vol. 176, No. 4, 01.10.2006, p. 1409-1414.

Research output: Contribution to journalArticle

Ray, Michael E. ; Mehra, Rohit ; Sandler, Howard M. ; Daignault, Stephanie ; Shah, Rajal B. / E-Cadherin Protein Expression Predicts Prostate Cancer Salvage Radiotherapy Outcomes. In: Journal of Urology. 2006 ; Vol. 176, No. 4. pp. 1409-1414.
@article{01c73599111f46c6871ac7a892d0bf9b,
title = "E-Cadherin Protein Expression Predicts Prostate Cancer Salvage Radiotherapy Outcomes",
abstract = "Purpose: Radiotherapy for biochemical prostate cancer recurrence after prostatectomy achieves durable salvage rates of only 40{\%} to 50{\%}. Improved methods of identifying patients unlikely to benefit from salvage radiotherapy are needed. Altered expression of the adhesion molecule E-cadherin may be associated with the invasive and metastatic phenotype. We examined the relationship between E-cadherin expression and outcomes after salvage radiotherapy. Materials and Methods: E-cadherin expression was examined by immunohistochemistical analysis of a tissue microarray of prostatectomy tissues from patients who underwent salvage radiotherapy. The relation between E-cadherin staining, other risk factors and biochemical failure after salvage radiotherapy was analyzed using Kaplan-Meier and Cox regression methods. Results: Of 37 analyzable cases 25 showed aberrant E-cadherin expression, while the remainder had normal expression. At a median clinical followup of 40 months univariate analysis demonstrated that E-cadherin staining was not associated with Gleason score, extracapsular extension, surgical margin status, pre-prostatectomy or pre-radiotherapy prostate specific antigen, complete biochemical response after radiotherapy or adjunctive hormonal therapy but it was associated with seminal vesicle invasion. Two-year failure-free survival was 55{\%} in patients with aberrant E-cadherin expression compared with 92{\%} in patients with normal E-cadherin expression (p = 0.02). Multivariate analysis confirmed that aberrant E-cadherin expression was associated with salvage radiotherapy failure (p = 0.03). Conclusions: Aberrant E-cadherin staining is associated with increased biochemical failure rates after salvage radiotherapy. Patients with biochemical failure after prostatectomy and aberrant E-cadherin expression are likely to have subclinical disseminated disease. Early systemic therapy may be warranted in these patients.",
keywords = "cadherins, prostate, prostatic neoplasms, radiotherapy, salvage therapy",
author = "Ray, {Michael E.} and Rohit Mehra and Sandler, {Howard M.} and Stephanie Daignault and Shah, {Rajal B.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1016/j.juro.2006.06.014",
language = "English (US)",
volume = "176",
pages = "1409--1414",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - E-Cadherin Protein Expression Predicts Prostate Cancer Salvage Radiotherapy Outcomes

AU - Ray, Michael E.

AU - Mehra, Rohit

AU - Sandler, Howard M.

AU - Daignault, Stephanie

AU - Shah, Rajal B.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Purpose: Radiotherapy for biochemical prostate cancer recurrence after prostatectomy achieves durable salvage rates of only 40% to 50%. Improved methods of identifying patients unlikely to benefit from salvage radiotherapy are needed. Altered expression of the adhesion molecule E-cadherin may be associated with the invasive and metastatic phenotype. We examined the relationship between E-cadherin expression and outcomes after salvage radiotherapy. Materials and Methods: E-cadherin expression was examined by immunohistochemistical analysis of a tissue microarray of prostatectomy tissues from patients who underwent salvage radiotherapy. The relation between E-cadherin staining, other risk factors and biochemical failure after salvage radiotherapy was analyzed using Kaplan-Meier and Cox regression methods. Results: Of 37 analyzable cases 25 showed aberrant E-cadherin expression, while the remainder had normal expression. At a median clinical followup of 40 months univariate analysis demonstrated that E-cadherin staining was not associated with Gleason score, extracapsular extension, surgical margin status, pre-prostatectomy or pre-radiotherapy prostate specific antigen, complete biochemical response after radiotherapy or adjunctive hormonal therapy but it was associated with seminal vesicle invasion. Two-year failure-free survival was 55% in patients with aberrant E-cadherin expression compared with 92% in patients with normal E-cadherin expression (p = 0.02). Multivariate analysis confirmed that aberrant E-cadherin expression was associated with salvage radiotherapy failure (p = 0.03). Conclusions: Aberrant E-cadherin staining is associated with increased biochemical failure rates after salvage radiotherapy. Patients with biochemical failure after prostatectomy and aberrant E-cadherin expression are likely to have subclinical disseminated disease. Early systemic therapy may be warranted in these patients.

AB - Purpose: Radiotherapy for biochemical prostate cancer recurrence after prostatectomy achieves durable salvage rates of only 40% to 50%. Improved methods of identifying patients unlikely to benefit from salvage radiotherapy are needed. Altered expression of the adhesion molecule E-cadherin may be associated with the invasive and metastatic phenotype. We examined the relationship between E-cadherin expression and outcomes after salvage radiotherapy. Materials and Methods: E-cadherin expression was examined by immunohistochemistical analysis of a tissue microarray of prostatectomy tissues from patients who underwent salvage radiotherapy. The relation between E-cadherin staining, other risk factors and biochemical failure after salvage radiotherapy was analyzed using Kaplan-Meier and Cox regression methods. Results: Of 37 analyzable cases 25 showed aberrant E-cadherin expression, while the remainder had normal expression. At a median clinical followup of 40 months univariate analysis demonstrated that E-cadherin staining was not associated with Gleason score, extracapsular extension, surgical margin status, pre-prostatectomy or pre-radiotherapy prostate specific antigen, complete biochemical response after radiotherapy or adjunctive hormonal therapy but it was associated with seminal vesicle invasion. Two-year failure-free survival was 55% in patients with aberrant E-cadherin expression compared with 92% in patients with normal E-cadherin expression (p = 0.02). Multivariate analysis confirmed that aberrant E-cadherin expression was associated with salvage radiotherapy failure (p = 0.03). Conclusions: Aberrant E-cadherin staining is associated with increased biochemical failure rates after salvage radiotherapy. Patients with biochemical failure after prostatectomy and aberrant E-cadherin expression are likely to have subclinical disseminated disease. Early systemic therapy may be warranted in these patients.

KW - cadherins

KW - prostate

KW - prostatic neoplasms

KW - radiotherapy

KW - salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=33748098541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748098541&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2006.06.014

DO - 10.1016/j.juro.2006.06.014

M3 - Article

C2 - 16952645

AN - SCOPUS:33748098541

VL - 176

SP - 1409

EP - 1414

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -